Trial Profile
A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Inebilizumab (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors MedImmune
- 05 Apr 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2019 This trial has been completed in Belgium.
- 03 Jan 2019 Planned End Date changed from 28 Dec 2018 to 29 Mar 2018.